Provectus Pharmaceuticals' Patent Application Published for Combining Local and
Systemic Therapies for Enhanced Treatment of Cancer
Business Wire News Release
PVCT
Provectus Pharmaceuticals Inc
2012-09-28T10:18:00-04:00
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Sep. 28, 2012-- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT,
pvct.com), a development-stage oncology and dermatology biopharmaceutical company,
announced that a patent application has been published for U.S. and international patents covering the
combination of local and systemic immunomodulative therapies for cancer treatment.
The patent, entitled "Combination of Local and Systemic Immunomodulative Therapies for Enhanced
Treatment of Cancer," covers a method of treatment of cancer that comprises administering a therapeutically
effective amount of an intralesional chemoablative pharmaceutical composition in combination with a
therapeutically effective amount of a systemic immunomodulatory anticancer agent. The systemic
immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies including ipilimumab and
tremelimumab.
Dr. Craig Dees, PhD, CEO of Provectus said, “We are pleased that this joint patent application has been
published as we continue to develop our intellectual property claims. We are excited about the potential of
combining PV-10, our intralesional chemoablative therapy, with other anticancer agents as appropriate, and
expanding its use in broader applications."
This patent can be accessed at the following link:
patentscope.wipo.int |
